AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) rose 3.6% during trading on Thursday . The stock traded as high as $3.15 and last traded at $3.14, with a volume of 143,112 shares. The stock had previously closed at $3.03.

ACRX has been the topic of several analyst reports. Jefferies Group reissued a “buy” rating on shares of AcelRx Pharmaceuticals in a report on Friday, June 10th. Cowen and Company reissued a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Monday, May 2nd. HC Wainwright reissued a “buy” rating and issued a $7.00 target price (down from $9.00) on shares of AcelRx Pharmaceuticals in a report on Tuesday, May 3rd. Seaport Global Securities raised AcelRx Pharmaceuticals from an “accumulate” rating to a “buy” rating in a report on Friday, May 6th. Finally, Janney Montgomery Scott started coverage on AcelRx Pharmaceuticals in a report on Thursday, April 14th. They issued a “neutral” rating on the stock. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $7.63.

The stock’s 50-day moving average price is $2.92 and its 200 day moving average price is $3.31. The firm’s market cap is $164.48 million.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last released its quarterly earnings data on Thursday, July 28th. The specialty pharmaceutical company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.02. The company had revenue of $4.53 million for the quarter, compared to analyst estimates of $2.17 million. On average, analysts predict that AcelRx Pharmaceuticals Inc. will post ($0.89) EPS for the current year.

In other news, Director Mark G. Edwards acquired 15,000 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Thursday, May 12th. The shares were acquired at an average price of $3.15 per share, with a total value of $47,250.00. Following the purchase, the director now directly owns 105,000 shares of the company’s stock, valued at $330,750. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Howard B. Rosen acquired 10,206 shares of AcelRx Pharmaceuticals stock in a transaction that occurred on Friday, May 13th. The shares were purchased at an average cost of $3.26 per share, for a total transaction of $33,271.56. Following the purchase, the chief executive officer now directly owns 50,000 shares in the company, valued at $163,000. The disclosure for this purchase can be found here.

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.